Trade

with

Dr Reddy Laboratories Ltd
(NYSE: RDY)
AdChoices
48.84
+0.01
+0.02%
After Hours :
48.61
-0.23
-0.46%

Open

48.75

Previous Close

48.83

Volume (Avg)

190.78k (249.03k)

Day's Range

48.40-48.84

52Wk Range

38.00-53.67

Market Cap.

8.32B

Dividend Rate (Yield )

0.28 (0.58%)

Beta

0.75

Shares Outstanding

170.34M

P/E Ratio (EPS)

21.98 (2.23)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 2.16B

    • Net Income

    • 351.08M

    • Market Cap.

    • 8.32B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 16.85

    • PEG (Price/Earnings Growth) Ratio

    • 1.48

    • Beta

    • 0.75

    • Forward P/E

    • 21.98

    • Price/Sales

    • 3.71

    • Price/Book Value

    • 5.31

    • Price/Cash flow

    • 26.18

      • EBITDA

      • 570.97M

      • Return on Capital %

      • 14.43

      • Return on Equity %

      • 27.25

      • Return on Assets %

      • 14.43

      • Book Value/Share

      • 0.15

      • Shares Outstanding

      • 170.34M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.28 (8/1/2014)

      • Dividend Declaration Date

      • 6/9/2014

      Analyst Recommendation
      10/17/2014
      Hold
        • 1 Year Price Target

        • 41.66

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 2.24

        • Cashflow Estimate

        • 2.33

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 23.60

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • 28.20

          • -26.33

          • Net Income

            Q/Q (last year)

          • 52.50

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 13.74

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • 39.44

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 58.77

            • 64.72

            • Pre-Tax Margin

            • 21.22

            • 13.77

            • Net Profit Margin

            • 16.85

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 54.00

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 15.50

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 12.30

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.20

              • 0.33

              • Current Ratio

              • 2.00

              • 1.52

              • Quick Ratio

              • 1.31

              • 0.87

              • Interest Coverage

              • 23.68

              • 6.77

              • Leverage Ratio

              • 1.79

              • 1.91

              • Book Value/Share

              • 9.25

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 21.88

                • 63.29

                • P/E Ratio 5-Year High

                • 24.03

                • 237.47

                • P/E Ratio 5-Year Low

                • 8.65

                • 19.71

                • Price/Sales Ratio

                • 3.68

                • 3.53

                • Price/Book Value

                • 5.28

                • 3.31

                • Price/Cash Flow Ratio

                • 26.18

                • 21.23

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 27.25

                    (21.40)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • 14.43

                    (10.80)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • 18.98

                    (15.00)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • 1.27M

                  • 27.79k

                  • Inventory Turnover

                  • 2.39

                  • 1.80

                  • Asset Turnover

                  • 0.86

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  424.84M
                  Operating Margin
                  19.70
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  26.18
                  Ownership

                  Institutional Ownership

                  17.18%

                  Top 10 Institutions

                  8.15%

                  Mutual Fund Ownership

                  5.55%

                  Float

                  -

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • AXA Financial First State Asia Pac Ldr

                  •  

                    965,104

                  • 0.00

                  • 0.57

                  • Vanguard Emerging Markets Stock Idx Fund

                  •  

                    913,517

                  • 0.55

                  • 0.54

                  • BlackRock ISF Emerg Mkts Idx Sub-Fund

                  •  

                    664,765

                  • 0.00

                  • 0.39

                  • Aviva FirstState Glbl EM Ldrs

                  •  

                    484,470

                  • 0.00

                  • 0.28

                  • JPM Global Healthcare

                  •  

                    383,549

                  • 0.00

                  • 0.23

                  • Fidelity FAST Emerging Markets Fund

                  •  

                    312,477

                  • 10.42

                  • 0.18

                  • Pictet-Generics

                  •  

                    251,392

                  • -4.46

                  • 0.15

                  • Vanguard Total Intl Stock Idx Fund

                  •  

                    231,661

                  • 1.06

                  • 0.14

                  • Fisher Invts Instl Emerg Mkts Eq Fd

                  •  

                    206,900

                  • 41.59

                  • 0.12

                  • iShares MSCI Emerging Markets Dist

                  •  

                    191,429

                  • 2.41

                  • 0.11

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fisher Asset Management, LLC

                  •  

                    3,773,114

                  • +62.43%

                  • 2.22

                  • Colonial First State Glbl Asset Mgmt

                  •  

                    2,582,490

                  • +11.21%

                  • 1.52

                  • Fidelity International Ltd

                  •  

                    1,564,663

                  • +10.61%

                  • 0.92

                  • Vanguard Group, Inc.

                  •  

                    1,266,962

                  • -3.82%

                  • 0.74

                  • AXA Financial Limited

                  •  

                    965,104

                  • 0.00%

                  • 0.57

                  • BlackRock Fund Advisors

                  •  

                    895,261

                  • +2.35%

                  • 0.53

                  • Hansberger Global Investors Inc

                  •  

                    867,997

                  • +2,704.33%

                  • 0.51

                  • Schroder Investment Management Ltd.

                  •  

                    752,561

                  • -19.50%

                  • 0.44

                  • BlackRock Investment Management (UK) Ltd.

                  •  

                    644,003

                  • -21.48%

                  • 0.38

                  • AQR Capital Management LLC

                  •  

                    538,245

                  • +49.37%

                  • 0.32

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Speculative Growth

                  Style

                  Large Growth

                  Dr Reddy Laboratories Ltd was incorporated in India as a Private Limited Company on February 24, 1984. The Company converted to a Public Limited Company on December 6, 1985. The Company together with its subsidiaries is an India-base...mored pharmaceutical company engaged in manufacturing of pharmaceutical products. The Company operates through three segments; Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. The Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (“APIs”), Custom Pharmaceutical Services (“CPS”), generics, biosimilars, differentiated formulations and New Chemical Entities (“NCEs”). The Global Generics segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under ...morea brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company’s biologics business. The Pharmaceutical Services and Active Ingredients segment includes active pharmaceutical ingredients and intermediaries, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediaries become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment includes the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. The Company’s differentiated formulations portfolio consists of new, synergistic combinations and technologies that improve safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment also includes the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The Company's products includes; Zoledronic acid, Azacitidine, Moxifloxacin, Decitabine, Donepezil 23 mg, and Sumatriptan Auto Injector. The Company’s competitors include Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Alkem Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited, Emcure Pharmaceuticals Limited. Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Limited, Nycomed International Management GmbH and Zentiva N.V. The Company’s manufacturing and marketing of drugs, drug products and cosmetics is governed by many statutes, regulations and guidelines, including; Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945; Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954; Medicinal and Toilet Preparations (Excise Duties) Act, 1955; and National Pharmaceuticals Pricing Policy, 2012.lessless

                  Key People

                  Mr. G.V. Prasad

                  CEO/Director/Chairman of the Board

                  Mr. Saumen Chakraborty

                  CFO/Other Corporate Officer/President

                  Mr. Satish Reddy

                  Vice Chairman/Director/Managing Director

                  Dr. Cartikeya Reddy

                  Other Corporate Officer/Executive VP

                  Mr. Umang Vohra

                  Executive VP, Divisional

                  • Dr Reddy Laboratories Ltd

                  • 8-2-337, Road No. 3

                  • Hyderabad, Telangana 500034

                  • IND.Map

                  • Phone: +91 4049002900

                  • Fax: +91 4049002999

                  • drreddys.com

                  Incorporated

                  1984

                  Employees

                  18,421

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: